The U.S. Food and Drug Administration approved a new drug called Aduhelm (aducanumab) to treat Alzheimer’s disease, the most common form of dementia. Many are applauding the drug and are encouraged by the scientific progress in a field that has long had limited treatment options. Alzheimer’s affects over 6.2 million people in the U.S., with Latinos being 1.5 times more likely to develop it than white people. “What's really exciting is that aducanumab is the first new FDA-approved Alzheimer's treatment in nearly 20 years, and we're optimistic this will spark a wave of new research and innovation in this space. Patients are excited for that, too, and if aducanumab is the first step toward that brighter future, patients are eager to be part of it,” said Dr. Rany Aburashed, ...
U.S. Latinos are 1.5 times more likely than whites to develop Alzheimer’s disease. In fact, the number of Latinos with Alzheimer’s and dementia could increase six-fold, from 200,000 today to 1.3 million by 2050, according to the Alzheimer’s Association. We need to raise awareness. We also need advocacy for solutions. Fortunately, our Salud America! #SaludTues Tweetchats, a discussion series on Twitter about Latino health, helped raise awareness of and advocacy action around Alzheimer's and its rise among Latinos, according to our new study in the Journal of Health Communication. The study found that #SaludTues Tweetchats provided a unique forum for sharing facts, increasing exposure, and discussing solutions to Alzheimer's among Latinos. "The study proves that ...
Many studies are uncovering an alarming link between COVID-19 and dementia. One study found that more than 80% of 509 hospitalized COVID-19 patients had "neurologic manifestations," according to Northwestern Medicine. The brain inflammation and mini-strokes observed in COVID-19 patients may increase their risk of developing Alzheimer’s disease and other dementia, another study found. Now a new study from the UK found that people diagnosed with COVID-19 in the previous six months were more likely to develop depression, dementia, psychosis and stroke. "The study confirms the researchers suspicions that a COVID-19 diagnosis is not just related to respiratory symptoms, it is also related to psychiatric and neurological problems", Prof Dame Til Wykes, at the Institute of ...
